Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
95 studies found for:    myeloma AND (women OR woman OR female)
Show Display Options
Rank Status Study
21 Completed
Has Results
Bone Marker Assessment of Multiple Myeloma Patients Treated With Aminobisphosphonates
Condition: Multiple Myeloma
Intervention: Drug: Zoledronic acid
22 Active, not recruiting A Phase I Study Of Panobinostat/Lenalidomide/Bortezomib/Dex for Relapsed And Relapsed/Refractory Multiple Myeloma
Condition: Multiple Myeloma in Relapse
Interventions: Drug: Panobinostat;   Drug: Dexamethasone;   Drug: Lenalidomide;   Drug: Bortezomib
23 Not yet recruiting Propylene Glycol-Free Melphalan HCl (EVOMELA®) in Combination With Fludarabine and Total Body Irradiation Based Reduced Intensity Conditioning for Haploidentical Transplantation
Conditions: Hematological Malignancy Undergoing a Related Donor Haploidentical HCT;   Leukemia;   Multiple Myeloma;   Lymphoma
Interventions: Drug: Evomela;   Drug: Fludarabine;   Radiation: Total Body Irradiation
24 Completed
Has Results
Bortezomib, Lenalidomide, and Dexamethasone Combination Therapy for Patients With Relapsed or Relapsed and Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Bortezomib;   Drug: Lenalidomide;   Drug: Dexamethasone
25 Active, not recruiting Preservation of Ovarian Function After Hematopoietic Cell Transplant
Conditions: Multiple Myeloma;   Non-Hodgkin Lymphoma;   Hodgkin Disease;   Acute Myeloid Leukemia;   Myeloproliferative Disorders
Interventions: Drug: Leuprolide;   Biological: hematopoietic cell transplant;   Biological: reduced intensity allogeneic HCT
26 Recruiting Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma
Conditions: Light Chain Deposition Disease;   Smoldering Plasma Cell Myeloma
Interventions: Other: Clinical Observation;   Other: Laboratory Biomarker Analysis;   Drug: Lenalidomide;   Other: Quality-of-Life Assessment
27 Active, not recruiting Blockade of PD-1 in Conjunction With the Dendritic Cell/Myeloma Vaccines Following Stem Cell Transplantation
Condition: Multiple Myeloma
Interventions: Drug: CT-011;   Biological: Dendritic Cell Fusion Vaccine
28 Completed RAD001 and Lenalidomide in the Treatment of Subjects With Relapsed and Relapsed/Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: RAD001;   Drug: lenalidomide
29 Active, not recruiting
Has Results
Bortezomib, Lenalidomide and Dexamethasone Combination Therapy in Patients With Newly Diagnosed Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Bortezomib;   Drug: Lenalidomide;   Drug: dexamethasone
30 Recruiting S1211 Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma
Conditions: DS Stage I Plasma Cell Myeloma;   DS Stage II Plasma Cell Myeloma;   DS Stage III Plasma Cell Myeloma
Interventions: Drug: Bortezomib;   Drug: Dexamethasone;   Biological: Elotuzumab;   Other: Laboratory Biomarker Analysis;   Drug: Lenalidomide
31 Completed Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Lenalidomide and low-dose dexamethasone;   Drug: Lenalidomide plus low-dose dexamethasone given for 18 four-week cycles;   Drug: Melphalan, Prednisone and Thalidomide
32 Terminated Plerixafor (AMD3100) and Bevacizumab for Recurrent High-Grade Glioma
Conditions: High Grade Glioma: Glioblastoma (GBM);   High Grade Glioma: Gliosarcoma;   Anaplastic Astrocytoma (AA);   Anaplastic Oligodendroglioma (AO);   Mixed Anaplastic Oligoastrocytoma (AOA)
Interventions: Drug: Plerixafor;   Drug: Bevacizumab;   Procedure: Surgery
33 Completed CD8+ T Cell Depletion for GVHD Prophylaxis After Peripheral Blood Stem Cell Transplantation
Conditions: Hematologic Malignancy;   AML;   ALL;   CML;   Multiple Myeloma;   NHL;   Hodgkin's Lymphoma
Intervention: Device: CD+8 T cell depletion
34 Active, not recruiting Lenalidomide/Bortezomib/Dexamethasone for Multiple Myeloma (MM)
Condition: Multiple Myeloma
Interventions: Drug: Lenalidomide;   Drug: Bortezomib;   Drug: Dexamethasone
35 Not yet recruiting Single Agent ONC201 in Recurrent or Metastatic Endometrial Cancer
Condition: Endometrial Cancer
Intervention: Drug: ONC201
36 Recruiting NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma
Conditions: Advanced Malignant Solid Neoplasm;   Lymphoma;   Recurrent Malignant Solid Neoplasm;   Recurrent Plasma Cell Myeloma;   Refractory Malignant Neoplasm;   Refractory Plasma Cell Myeloma
Interventions: Drug: Afatinib;   Drug: Akt inhibitor AZD5363;   Drug: Binimetinib;   Drug: Crizotinib;   Other: Cytology Specimen Collection Procedure;   Drug: Dabrafenib;   Drug: Dasatinib;   Drug: Defactinib;   Drug: FGFR Inhibitor AZD4547;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab;   Drug: Osimertinib;   Drug: Palbociclib;   Biological: Pertuzumab;   Drug: PI3K-beta Inhibitor GSK2636771;   Drug: Sapanisertib;   Drug: Sunitinib Malate;   Drug: Taselisib;   Drug: Trametinib;   Biological: Trastuzumab Emtansine;   Drug: Trk Inhibitor LOXO-101;   Drug: Vismodegib;   Drug: WEE1 Inhibitor AZD1775
37 Terminated
Has Results
Pomalidomide, Dexamethasone and Rituximab in Waldenstrom's Macroglobulinemia
Condition: Waldenstrom's Macroglobulinemia
Interventions: Drug: pomalidomide;   Drug: dexamethasone;   Drug: rituximab
38 Completed
Has Results
Allo Non-Myeloablative SCT Utilizing Mis-Matched Family Member Stem Cells Purged Using Campath
Conditions: Lymphoma;   Myeloma;   Leukemia;   Myelodysplasia;   Solid Tumors
Interventions: Drug: Campath Purged Non-myeloablative ASCT;   Procedure: Donor Apheresis
39 Unknown  Busulfan and Melphalan Conditioning in Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: BUSULFEX®;   Drug: Alkeran®
40 Recruiting Pomalidomide and Dexamethasone With or Without Ixazomib in Treating Patients With Refractory Multiple Myeloma
Condition: Multiple Myeloma in Relapse
Interventions: Drug: pomalidomide;   Drug: ixazomib;   Drug: dexamethasone

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.